Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts 
Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58% 
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal 
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict 
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand 
Lumentum Holdings Rides AI Wave With Order Book Filled Through 2028 
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs 
NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy 
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles 
NEW HAVEN, Conn., Aug. 09, 2016 -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Milind Deshpande, Ph.D., President and Chief Executive Officer of Achillion, will present a corporate overview at the 2016 Wedbush PacGrow Healthcare Conference on Tuesday, August 16, 2016 at 10:55am EDT at the Le Parker Meridien Hotel in New York City, NY.
The live audio and subsequent archived webcasts of the Company's presentations will be accessible from the Company's investor relations website, http://ir.achillion.com. The audio recording will be archived for 30 days following the live presentation. Please connect to Achillion's website several minutes prior to the start of the presentation to ensure adequate time for any software downloads that may be necessary.
About Achillion Pharmaceuticals
Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) is a science-driven, patient-focused company seeking to leverage its strengths across the continuum from discovery to commercialization in its goal of providing better treatments for people with serious diseases. The company employs a highly-disciplined discovery and development approach that has allowed it to pursue best-in-class oral antiviral therapy for chronic hepatitis C (HCV) and build a platform of potent and specific complement inhibitors. Achillion is rapidly advancing its efforts to become a fully-integrated pharmaceutical company with a goal of bringing life-saving medicines to patients with rare diseases. More information is available at http://www.achillion.com.
Investors: Glenn Schulman Achillion Pharmaceuticals, Inc. Tel. (203) 752-5510 [email protected] Media: Liz Power Achillion Pharmaceuticals, Inc. Tel: (203) 752-5509 [email protected]
